Xiaolin Wang - 01 Mar 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role: EVP, Clinical Development
Signature: /s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang
Issuer symbol: RVMD
Transactions as of: 01 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 03 Mar 2026, 21:11:14 UTC
Previous filing: 19 Mar 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Wang Xiaolin	EVP, Clinical Development	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY	/s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang	03 Mar 2026	0001849181

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RVMD	Common Stock	Award	$0	+15,100	+15%	$0.000000	118,073	01 Mar 2026	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RVMD	Stock Option (Right to Buy)	Award	$0	+34,000		$0.000000	34,000	01 Mar 2026	Common Stock	34,000	$102.02	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 54,464 restricted stock units.
F2	Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.
F3	One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

EVP, Clinical Development